Levobetaxolol

Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Routes of administration	topical (ophthalmic)
ATC code	none
Pharmacokinetic data
Elimination half-life	20 hours
Identifiers
IUPAC name (S)-1-2-(cyclopropylmethoxy)ethylphenoxy-3-(isopropylamino)-2-propanol hydrochloride
CAS Number	93221-48-8 N
PubChem CID	60657
IUPHAR/BPS	8035
ChemSpider	54669 Y
UNII	75O9XHA4TU
ChEBI	CHEBI:59254 Y
ChEMBL	ChEMBL1201274 N
CompTox Dashboard (EPA)	DTXSID30239341
Chemical and physical data
Formula	C18H29NO3
Molar mass	307.434 g·mol−1
3D model (JSmol)	Interactive image
SMILES O(CCc1ccc(OCC@@H(O)CNC(C)C)cc1)CC2CC2
InChI InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3/t17-/m0/s1 Y Key:NWIUTZDMDHAVTP-KRWDZBQOSA-N Y
NY (what is this?)  (verify)

Levobetaxolol is a drug used to lower the pressure in the eye in treating conditions such as glaucoma. It is marketed as a 0.25 or 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon. Levobetaxolol is a beta-adrenergic receptor inhibitor (beta blocker).

Indicationsedit

It is indicated for intraocular pressure reduction in patients with open-angle glaucoma or ocular hypertension.^[1]

Effectedit

Levobetaxolol inhibits the beta-1-adrenergic receptor. When applied topically, it reduces intra-ocular pressure (IOP) by 16-23% depending on time of day and the individual. It also has neuroprotective effects.^[1] Levobetaxolol has fewer cardiovascular side effects than other beta blockers.

Contraindications and side effectsedit

Levobetaxolol should not be used by people who have sinus bradycardia, atrioventricular block, cardiogenic shock, or overt cardiac failure. The drug has been associated with bradycardia and hypertension.^{[citation needed]}

Historyedit

Levobetaxolol was developed in the 1980s.^[1] It was FDA approved in 2000.^[2]

Referencesedit